Immune Thrombocytopenia natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
(some parts of natural history)
(overview completed)
 
(One intermediate revision by the same user not shown)
Line 5: Line 5:


==Overview==
==Overview==
The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding. Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].


Line 24: Line 26:
===Complications===
===Complications===


*Common complications of [disease name] include:
*Common complications of immune thrombocytopenia include:
**[Complication 1]
**Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.)
**[Complication 2]
**Infection ( due to splenectomy or immunosuppressive medications)
**[Complication 3]
**[Complication 3]


===Prognosis===
===Prognosis===


*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
*Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.<ref name="KohliChaturvedi20192">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref>
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].

Latest revision as of 14:43, 8 March 2021

Immune Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Immune Thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Immune Thrombocytopenia natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Immune Thrombocytopenia natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Immune Thrombocytopenia natural history, complications and prognosis

CDC on Immune Thrombocytopenia natural history, complications and prognosis

Immune Thrombocytopenia natural history, complications and prognosis in the news

Blogs on Immune Thrombocytopenia natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Immune Thrombocytopenia natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

Overview

The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding. Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

OR

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

OR

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of chronic immune thrombocytopenia usually develop in the any decade of life, many patients are asymptomatic however about two third of patients start with symptoms such as mucocutaneous , gastrointestinal and genitourinary bleeding.[1][2]
  • The symptoms of (disease name) typically develop ___ years after exposure to ___.
  • If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Complications

  • Common complications of immune thrombocytopenia include:
    • Thromboembolic risk ( the risk of thromboembolism, in ITP is twice higher than general population.)
    • Infection ( due to splenectomy or immunosuppressive medications)
    • [Complication 3]

Prognosis

  • Prognosis is generally excellent/good/poor, and the 5-10-year mortality rate of patients with ITP is approximately 22-34% respectfully.[3]
  • Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
  • The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
  • [Subtype of disease/malignancy] is associated with the most favorable prognosis.
  • The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.

References

  1. . doi:10.2147/JBM.S289390. Check |doi= value (help). Missing or empty |title= (help)
  2. Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
  3. Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.

Template:WH Template:WS